Ac­celeron un­corks more mid-stage da­ta for PAH drug so­tater­cept as part of the drug's res­ur­rec­tion cam­paign

Once on life sup­port in pul­monary ar­te­r­i­al hy­per­ten­sion, Ac­clereron’s so­tater­cept came back from the brink with win­ning da­ta ear­ly last year. Now, with Phase III piv­otal stud­ies on the way, Ac­celeron is adding more da­ta to its scrap­book in prepa­ra­tion for an even­tu­al sit-down with reg­u­la­tors.

PAH pa­tients treat­ed with Ac­celeron’s so­tater­cept showed im­prove­ments across a broad range of out­comes, in­clud­ing peak oxy­gen up­take or VO2 max, as well as ven­ti­la­to­ry ef­fi­cien­cy, to­tal work­load and ar­te­ri­ove­nous oxy­gen con­tent, ac­cord­ing to ear­ly da­ta from the open-la­bel Phase II SPEC­TRA II pre­sent­ed at the Amer­i­can Tho­racic So­ci­ety meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER